

28 May 2026

TGA Update to Accelerate Empax Therapist Recruitment

Regulatory Catalyst broadens Emyria's Empax Clinic Recruitment Profile

Key Highlights:

- **Updated TGA Recommendations facilitate and accelerate recruitment to Empax clinic's 100+ strong Australia-wide clinician network**, broadening eligible disciplines required as part of the psychedelic-assisted psychotherapy dyad¹.
- **Emyria welcomes the recommendations** including scope expansion for additional therapists to include Aboriginal and Torres Strait Islander Health workers to support culturally safe care in Australia.
- **Company expects benefits to take effect H2 CY2026** after final TGA endorsement, workforce planning, recruitment and training.

Emyria Limited (ASX: EMD) ("Emyria", or the "Company"), a leader in innovative mental health treatments, welcomes the Therapeutic Goods Administration's (TGA) announcement of changes to its recommendations for the Authorised Prescriber (AP) scheme for psychedelic-assisted psychotherapy (PAT).

The updated recommendations expand the range of clinicians required as one of the two therapists in the psychedelic-assisted psychotherapy "dyad", which to date has mandated a clinical psychologist or medical practitioner be present during dosing.

Under the changes, the TGA confirmed yesterday that the dyad can now include a broader range of trained therapists registered with one of the following national boards: psychology (with clinical endorsement), medical (general registration), nursing and midwifery (with mental health experience), or occupational therapy (where scope of practice includes psychedelic-assisted psychotherapy).

The Authorised Prescriber may then use professional discretion to determine other members of the therapy team that may be considered including psychotherapists, counsellors, social workers, and Aboriginal and Torres Strait Islander health workers.

Direct benefit to Emyria's national Empax network

The expanded eligible workforce is expected to:

- improve clinic utilisation through more flexible dyad configurations and reduced reliance on clinical psychologists;
- accelerate recruitment of appropriate therapists across each jurisdiction;
- diversify Emyria's clinical workforce, including supporting culturally appropriate care; and
- ultimately improve patient access to important treatment options across Emyria's national footprint.

Implementation pathway

The recommendations will require final approval before taking effect with benefits of the changes expected to be realised in H2 CY2026. Having previously successfully navigated the process on multiple occasions, Emyria will be required to update existing care models and submit for review by the Company's ethics committee before final endorsement by the TGA. The Company has already commenced revised workforce planning in preparation for the announced regulatory changes.

A positive signal from an engaged regulator

Emyria views the TGA's announcement as a positive and pragmatic adjustment reflecting growing real-world evidence and experience with psychedelic-assisted psychotherapy. The Company expects further pragmatic changes to the framework over time as clinical evidence and operational experience continue to grow.

Executive Chair Greg Hutchinson commented:

"This is a welcome and pragmatic step from the TGA. Broadening the disciplines that can lead psychedelic-assisted psychotherapy will directly support our recruitment efforts, help diversify our workforce, and improve utilisation and patient access across our national Empax network. We see this as recognition of a regulator that is willing to engage and respond, and we expect further sensible adjustments over time as the body of clinical evidence and real-world experience continues to grow."

This release has been approved by the Chair of Emyria.

For further information, investment opportunities, or more about Emyria's approach to mental health treatment, please contact:

Greg Hutchinson

Executive Chair

1300 436 363 | investors@emyria.com

References:

1. TGA, Targeted consultation on AP scheme for psychedelics <https://www.tga.gov.au/news/news-articles/updates-authorised-prescriber-ap-scheme-requirements-when-accessing-mdma-and-psilocybine>



Emyria Limited develops and delivers new treatments for mental health and select neurological conditions through an integrated model of direct clinical services and treatment development:

generates

Emyria Healthcare: Evidence-based treatment for patients not finding relief from conventional care while also helping evaluate emerging new therapies like assisted therapy for PTSD and assisted therapy for treatment-resistant depression.

informs

Emyria Data: Robust and ethically sourced Real-World Data gathered with patients to improve Emyria's unique therapy and drug development programs.

Emyria's Pipeline: New psychedelic-assisted therapies and drug treatments for mental health and select neurological diseases.

EMYRIA'S INTERACTIVE INVESTOR HUB

Investorhub.emyria.com Interact with Emyria's announcements and updates by asking questions and comments, which our team can respond to where possible.



CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

Risks associated with the use of MDMA, MDMA-inspired compounds and psilocybin

All medicines carry risks and specialist prescribers, such as registered psychiatrists, are best placed to assess the suitability of a new medication against a patient's individual circumstances and medical history before proceeding. Adverse effects of MDMA include high blood pressure, increased pulse rate, faintness, and panic attacks, and in some rare cases it can cause loss of consciousness or trigger seizures. Other side effects include involuntary jaw clenching, decreased appetite, restless legs, nausea, headache, sweating and muscle/joint stiffness. Adverse effects of psilocybin can include temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. The effects of MDMA and psilocybin are unlikely at low doses in the treatment regimens used in psychedelic-assisted psychotherapy while appropriately managed in a controlled environment with direct medical supervision. The risk profile of the MDMA inspired compounds is currently unknown.

The availability of these products is subject to the safety and efficacy of the products being tested through clinical trials. Emyria makes no representations or warranties as to the safety or efficacy of the products or the products' ability (or the ability of its key compounds) to be used in the treatment of indications such as PTSD. There are currently no approved products containing MDMA, psilocybin or MDMA inspired compounds that the TGA has evaluated for quality, safety and efficacy.